{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-033015","form_type":"8-K","ticker":"MBIO","cik":"0001680048","company_name":"MUSTANG BIO, INC.","filed_at":"2024-03-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.088720+00:00","generated_at":"2026-06-04T23:52:28.555360+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Mustang Bio reports FY2023 net loss of $51.6M; cash drops to $7.0M; MB-106 data positive","bullets":["Cash and cash equivalents $7.0M at Dec 31, 2023, down from $76.7M at Dec 31, 2022; $30.4M debt termination payment in 2023.","Net loss $51.6M ($6.00/share) vs $77.5M ($10.09/share) in 2022; R&D spend $40.5M vs $62.5M.","MB-106 Phase 1/2 multicenter trial: 100% ORR in FL (n=5 all CR) and WM (n=3 with VGPR/PR); no severe CRS/ICANS.","Registrational trial in Waldenstrom macroglobulinemia planned H2 2024; topline expected H2 2026; RMAT designation request H1 2024.","Closed uBriGene asset sale for $6M upfront; $5M contingent; lease assignment subject to CFIUS review."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-033015","json":"https://secwatch.observer/filing/0001104659-24-033015.json","markdown":"https://secwatch.observer/filing/0001104659-24-033015.md","text":"https://secwatch.observer/filing/0001104659-24-033015.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1680048/000110465924033015/0001104659-24-033015-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1680048/000110465924033015/tm248266d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T23:52:28.555360+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"70fd4d7be76084043fc0fff9f21bc49aa2b529b9","claim":"MUSTANG BIO, INC. reported the fiscal year ended December 31, 2023 results: net income $51.6 million, EPS $6.00 per share.","evidence_excerpt":"On March 11, 2024, Mustang Bio, Inc. issued a press release to provide a corporate update and to announce its financial results for the fiscal year ended December 31, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1680048/000110465924033015/0001104659-24-033015-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fiscal year ended December 31, 2023"},{"label":"Net income","value":"$51.6 million"},{"label":"EPS","value":"$6.00 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}